بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
reduced decrease » reduced disease (توسيع البحث), reported decrease (توسيع البحث), induces decreased (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
reduced decrease » reduced disease (توسيع البحث), reported decrease (توسيع البحث), induces decreased (توسيع البحث)
-
18461
Table 4_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
18462
Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18463
Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18464
Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18465
Supplementary file 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
18466
Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18467
Table 2_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
18468
Table 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
18469
Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18470
Rht1 functions in cell cycle progression and modulates fluconazole susceptibility.
منشور في 2025"…Log rank (Mantel-Cox) test assessed significant difference between wild type and <i><i>rht1</i></i>Δ/Δ. …"
-
18471
Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18472
Table 3_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
18473
Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18474
Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18475
Genetic interaction between <i>Zrf1</i> and RISC components regulates ISC proliferation during midgut damage.
منشور في 2025"…</b> Box plots show median, quartiles, and range. Statistical significance determined by Student’s t-test; ns = not significant, **p < 0.01, ****p < 0.0001.…"
-
18476
Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
منشور في 2025"…<b>A,</b> Inhibition of PDX-CDS #4-C tumor growth after treatments with trabectedin and/or NVP-BEZ235. Significant reduction in tumor growth was observed after single treatments (*, <i>P</i> < 0.05, Student <i>t</i> test) but the inhibition increased after combination of the two drugs (significance was at least ***, <i>P</i> < 0.001, Student <i>t</i> test starting from day 23) or to single treatments (*, <i>P</i> < 0.05). …"
-
18477
Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18478
Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18479
Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
18480
Table 7_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"